Study of Euthyroid Hypothyroxinemia in Metastatic Breast Carcinoma

Summary

Up to one third of breast cancer patients have hypothyroidism or hyperthyroidism. L-thyroxine (T4), or Synthroid, is the most commonly prescribed agent for the management of hypothyroidism in the US. However, there are data suggesting that triiodothyronine (T3) may have benefits in preventing disease progression over l-thyroxine (T4).

Timeline

Start

2019-03-01

Primary completion

2022-03-09

Completion

2022-03-09

Drugs

Indications